Original COVID-19 vaccine by Novavax receives FDAs nod as booster dose

By Ayushi Garg  | Date: October 20, 2022

Original COVID-19 vaccine by Novavax receives FDAs nod as booster dose

The original COVID-19 vaccine from Novavax Inc. (NVAX) has been reportedly approved by the Food and Drug Administration (FDA) to be used as a booster in select adults, making it the first monovalent vaccination to do so against the most recent Omicron variants.

According to the authorization, adults who have finished their primary vaccination series but have not yet had a bivalent booster shot are allowed to receive one dose of Novavax at least six months after their last shot. However, it is only for the cases where the patients initial dosages were mRNA and an mRNA-bivalent booster is not available or clinically suitable.

According to John Trizzino, Chief Commercial Officer (CCO) at Novavax, the business is currently preparing clinical trial data that it expects will be used to change the emergency use authorization (EUA) to add the provision for use as a second booster.

He stated that only the first boost dose was included in the data that they provided. Now, intuitively, it is to be assumed that if this is good enough to perform the first heterologous boost, then it should be good enough to perform the second as well.

They did, however, seek additional details and a timeframe for its availability, which Novovax does not yet have. Ordinarily, the Centers for Disease Control and Prevention’s (CDC) recommendation, which is still pending, comes after the FDAs action.

According to the CCO, at least 50% of adults have not received a booster shot for COVID and about 20% of adults have not yet received any COVID vaccination at all. Although mRNA doses for second boosters have been available since September, the uptake has been sluggish.

It is worth mentioning that about 5% of those who qualify have received an extra booster dose as of last week. According to the CDC, around 40% of individuals over the age of 50 and 46% of persons over the age of 65 have received their second dose.

Source Credit:


About Author

Ayushi Garg     ibmag.com

Ayushi Garg

Currently working as an associate content writer, Ayushi pens down insightful articles for several websites. She began her profession by taking classes in digital marketing to broaden her skills. Given her passion for writing, she took up several freelancing projects ...

Read More